• Ascentage Pharma highlighted 17 clinical updates already presented at the 2026 EHA meeting, spanning its two lead hematology drugs.
• Olverembatinib showed sustained activity across chronic myeloid leukemia settings, supporting broader use in patients who fail earlier TKIs.
• In newly diagnosed Ph+ ALL, updated POLARIS-1 results reinforced deep remissions with manageable safety, supporting its global Phase 3 strategy.
• An oral, chemotherapy-free olverembatinib–lisaftoclax regimen produced rapid responses in pediatric relapsed or refractory Ph+ ALL with a controllable profile.
• Lisaftoclax data supported effectiveness in BTKi-failed CLL/SLL, with real-world evidence also backing use in myeloid malignancies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.